Arthritis drug xeljanz XR under Real-World safety watch
NCT ID NCT04876781
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 31 times
Summary
This study is tracking the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 people in Korea who have moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as part of their normal care, and researchers watch for side effects and measure disease activity over about four years. The goal is to see how well the drug works and how safe it is in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE MODERATE TO SEVERE RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.